Australia markets closed

Angion Biomedica Corp. (ANGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5000+0.1800 (+13.64%)
At close: 04:00PM EDT
1.6000 +0.10 (+6.67%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3200
Open1.3200
Bid1.3500 x 1300
Ask1.6000 x 800
Day's range1.3100 - 1.5600
52-week range1.0750 - 15.9100
Volume199,965
Avg. volume93,904
Market cap44.938M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results

    -- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March 31, 2022. “In the first quarter of 2022, we made good p

  • GlobeNewswire

    Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

    -- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration’s (FD

  • GlobeNewswire

    Angion Announces Participation in Upcoming Investment Conference

    UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference. Angion’s President and CEO, Dr. Jay Venkatesan, will participate virtually in the H.C. Wainwright Global Investment Conference. Details are as follows: Event: H.C. Wainwright Global Invest